Holen Sie sich die Stockscreener-App
2.4283
5.97%
0.1683
Schlusskurs vom Vortag:
$2.26
Offen:
$2.29
24-Stunden-Volumen:
1.84M
Relative Volume:
1.67
Marktkapitalisierung:
$261.62M
Einnahmen:
$27.08M
Nettoeinkommen (Verlust:
$-37.00M
KGV:
-4.6698
EPS:
-0.52
Netto-Cashflow:
$-18.46M
1W Leistung:
-3.82%
1M Leistung:
+26.05%
6M Leistung:
+87.11%
1J Leistung:
+5.97%
1-Tages-Spanne:
$2.195
$2.6389
1-Wochen-Bereich:
$2.125
$2.70
52-Wochen-Spanne:
$1.05
$5.17
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Firmenname
Aclaris Therapeutics Inc
Sektor
Branche
Telefon
484-324-7933
Adresse
701 LEE ROAD, WAYNE, PA
Vergleichen Sie ACRS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
2.415 | 244.83M | 27.08M | -37.00M | -18.46M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.41 | 105.80B | 11.70B | 3.68B | 3.50B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.87 | 67.70B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
439.16 | 57.41B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
849.87 | 51.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
185.84 | 39.86B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-05-28 | Eingeleitet | Wedbush | Outperform |
| 2025-03-18 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2024-12-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-11-19 | Hochstufung | Jefferies | Hold → Buy |
| 2024-11-19 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | Eingeleitet | Evercore ISI | Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Buy |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2022-10-06 | Eingeleitet | BTIG Research | Buy |
| 2021-07-23 | Fortgesetzt | Jefferies | Buy |
| 2021-06-15 | Eingeleitet | Piper Sandler | Overweight |
| 2021-04-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-10-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | Eingeleitet | SVB Leerink | Outperform |
| 2018-03-28 | Fortgesetzt | Leerink Partners | Outperform |
| 2018-02-09 | Eingeleitet | Guggenheim | Buy |
| 2017-06-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-11-29 | Eingeleitet | Leerink Partners | Outperform |
| 2016-09-30 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-06-10 | Eingeleitet | Guggenheim | Buy |
| 2015-11-02 | Eingeleitet | Citigroup | Buy |
| 2015-11-02 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Aclaris Therapeutics Inc Aktie (ACRS) Neueste Nachrichten
How Aclaris Therapeutics Inc. (8AT) stock performs during market turbulenceTrend Reversal & Daily Momentum Trading Reports - newser.com
Can Aclaris Therapeutics Inc. stock deliver strong Q4 earningsQuarterly Growth Report & Community Verified Trade Signals - newser.com
Aclaris Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Aclaris Therapeutics Inc earnings beat by $0.01, revenue topped estimates - Investing.com
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Aclaris: Q3 Earnings Snapshot - San Francisco Chronicle
Aclaris Therapeutics shares Q3 financial results, stock in focus - Traders Union
Why Aclaris Therapeutics Inc. (8AT) stock gets analyst attentionWeekly Earnings Recap & Growth Focused Entry Point Reports - fcp.pa.gov.br
Aclaris Therapeutics Q3 revenue beats estimates, net loss narrows - TradingView
Will Aclaris Therapeutics Inc. stock deliver shareholder valueWeekly Market Summary & Target Return Focused Stock Picks - newser.com
Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Understanding Aclaris Therapeutics Inc.’s price movementQuarterly Growth Report & Capital Efficient Trading Techniques - newser.com
Is Aclaris Therapeutics Inc. stock a contrarian buy2025 Performance Recap & AI Forecast Swing Trade Picks - newser.com
Is Aclaris Therapeutics Inc. (8AT) stock a momentum leader2025 AllTime Highs & Real-Time Chart Breakout Alerts - newser.com
Why analysts recommend Aclaris Therapeutics Inc. (8AT) stockTake Profit & Smart Swing Trading Techniques - fcp.pa.gov.br
Risk adjusted return profile for Aclaris Therapeutics Inc. analyzedTrade Exit Summary & Reliable Price Breakout Alerts - newser.com
Statistical indicators supporting Aclaris Therapeutics Inc.’s strengthInflation Watch & Weekly Top Stock Performers List - newser.com
Why Aclaris Therapeutics Inc. (8AT) stock is a must watch tickerJuly 2025 Trends & Stepwise Trade Signal Implementation - newser.com
Can you recover from losses in Aclaris Therapeutics Inc.Weekly Trade Summary & Community Consensus Picks - newser.com
Applying chart zones and confluence areas to Aclaris Therapeutics Inc.July 2025 Outlook & Stepwise Entry/Exit Trade Alerts - newser.com
Will Aclaris Therapeutics Inc. stock outperform international peersMarket Activity Report & Entry Point Confirmation Signals - newser.com
What high frequency data says about Aclaris Therapeutics Inc.July 2025 Volume & Free Technical Confirmation Trade Alerts - newser.com
Corcept Therapeutics (CORT) Q3 Earnings and Revenues Miss Estimates - Yahoo Finance
Will Aclaris Therapeutics Inc. benefit from macro trendsPortfolio Gains Report & Risk Controlled Daily Plans - newser.com
How to use a screener to detect Aclaris Therapeutics Inc. breakoutsTrade Exit Report & Fast Exit Strategy with Risk Control - newser.com
Key resistance and support levels for Aclaris Therapeutics Inc.2025 Geopolitical Influence & Free Technical Pattern Based Buy Signals - newser.com
Will Aclaris Therapeutics Inc. (8AT) stock hit Wall Street targetsWeekly Profit Report & Fast Moving Stock Watchlists - newser.com
Using Python tools to backtest Aclaris Therapeutics Inc. strategiesJuly 2025 Analyst Calls & AI Enhanced Trading Signals - newser.com
Why Aclaris Therapeutics Inc. stock attracts global investorsMarket Sentiment Review & Verified Momentum Watchlists - newser.com
Aclaris Therapeutics (NASDAQ:ACRS) adds US$40m to market cap in the past 7 days, though investors from three years ago are still down 83% - Yahoo Finance
Finanzdaten der Aclaris Therapeutics Inc-Aktie (ACRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Aclaris Therapeutics Inc-Aktie (ACRS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mehra Anand | Director |
Nov 19 '24 |
Buy |
2.25 |
666,666 |
1,499,998 |
710,030 |
1.70%
2.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):